Ian F. Hermans

NKT Cells Enhance CD4+ and CD8+ T Cell Responses to Soluble Antigen In Vivo through Direct Interaction with Dendritic Cells

Modification in the function of dendritic cells (DC), such as that achieved by microbial stimuli or T cell help, plays a critical role in determining the quality and size of adaptive responses to Ag. NKT cells bearing an invariant TCR (iNKT cells) restricted by nonpolymorphic CD1d molecules may constitute a readily available source of help for DC. We therefore examined T cell responses to i.v. injection of soluble Ag in the presence or the absence of iNKT cell stimulation with the CD1d-binding glycolipid α-galactosylceramide (α-GalCer). Considerably enhanced CD4+ and CD8+ T cell responses were observed when α-GalCer was administered at the same time as or close to OVA injection. This enhancement was dependent on the involvement of iNKT cells and CD1d molecules and required CD40 signaling. Studies in IFN-γR−/− mice indicated that IFN-γ was not required for the adjuvant effect of α-GalCer. Consistent with this result, enhanced T cell responses were observed using OCH, an analog of α-GalCer with a truncated sphingosine chain and a reduced capacity to induce IFN-γ. Splenic DC from α-GalCer-treated animals expressed high levels of costimulatory molecules, suggesting maturation in response to iNKT cell activation. Furthermore, studies with cultured DC indicated that potentiation of T cell responses required presentation of specific peptide and α-GalCer by the same DC, implying conditioning of DC by iNKT cells. The iNKT-enhanced T cell responses resisted challenge with OVA-expressing tumors, whereas responses induced in the absence of iNKT stimulation did not. Thus, iNKT cells exert a significant influence on the efficacy of immune responses to soluble Ag by modulating DC function.

CD8+ T Cell-Dependent Elimination of Dendritic Cells In Vivo Limits the Induction of Antitumor Immunity

The fate of dendritic cells (DC) after they have initiated a T cell immune response is still undefined. We have monitored the migration of DC labeled with a fluorescent tracer and injected s.c. into naive mice or into mice with an ongoing immune response. DC not loaded with Ag were detected in the draining lymph node in excess of 7 days after injection with maximum numbers detectable ∼40 h after transfer. In contrast, DC that had been loaded with an MHC class I-binding peptide disappeared from the lymph node with kinetics that parallel the known kinetics of activation of CD8+ T cells to effector function. In the presence of high numbers of specific CTL precursors, as in TCR transgenic mice, DC numbers were significantly decreased by 72 h after injection. The rate of DC disappearance was extremely rapid and efficient in recently immunized mice and was slower in “memory” mice in which memory CD8+ cells needed to reacquire effector function before mediating DC elimination. We also show that CTL-mediated clearance of Ag-loaded DC has a notable effect on immune responses in vivo. Ag-specific CD8+ T cells failed to divide in response to Ag presented on a DC if the DC were targets of a pre-existing CTL response. The induction of antitumor immunity by tumor Ag-loaded DC was also impaired. Therefore, CTL-mediated clearance of Ag-loaded DC may serve as a negative feedback mechanism to limit the activity of DC within the lymph node.

Dendritic cells: a journey from laboratory to clinic

Dendritic cell–based vaccines have been rapidly transferred from the laboratory to the clinic. As the full potential of these cells has not yet been entirely exploited, many strategies could improve the immunogenicity of these vaccines.

CpG-matured murine plasmacytoid dendritic cells are capable of in vivo priming of functional CD8 T cell responses to endogenous but not exogenous antigens.

Plasmacytoid dendritic cells (PDCs) are a unique leukocyte population capable of secreting high levels of type I interferon (IFN) in response to viruses and bacterial stimuli. In vitro experiments have shown that upon maturation, human and murine PDCs develop into potent immunostimulatory cells; however, their ability to prime an immune response in vivo remains to be addressed. We report that CpG-matured murine PDCs are capable of eliciting in naive mice antigen-specific CTLs against endogenous antigens as well as exogenous peptides, but not against an exogenous antigen. Type I IFN is not required for priming, as injection of CpG-matured PDCs into type I IFN receptor–deficient mice elicits functional CTL responses. Mature PDCs prime CTLs that secrete IFN-γ and protect mice from a tumor challenge. In contrast, immature PDCs are unable to prime antigen-specific CTLs. However, mice injected with immature PDCs are fully responsive to secondary antigenic challenges, suggesting that PDCs have not induced long-lasting tolerance via anergic or regulatory T cells. Our results underline the heterogeneity and plasticity of different antigen-presenting cells, and reveal an important role of mature PDCs in priming CD8 responses to endogenous antigens, in addition to their previously reported ability to modulate antiviral responses via type I IFN.

Competition Between CTL Narrows the Immune Response Induced by Prime-Boost Vaccination Protocols

Recombinant vaccines encoding strings of virus- or tumor-derived peptides and/or proteins are currently being designed for use against both cancer and infectious diseases. These vaccines aim to induce cytotoxic immune responses against several Ags simultaneously. We developed a novel tetramer-based technique, based on chimeric HLA A2/H-2Kb H chains, to directly monitor the CTL response to such vaccines in HLA-A2 transgenic mice. We found that priming and boosting with the same polyepitope construct induced immune responses that were dominated by CTL of a single specificity. When a mixture of viruses encoding single proteins was used to boost the polyepitope primed response, CTL of multiple specificities were simultaneously expanded to highly effective levels in vivo. In addition, we show that a preexisting response to one of the epitopes encoded within a polyepitope construct significantly impaired the ability of the vaccine to expand CTL of other specificities. Our findings define a novel vaccination strategy optimized for the induction of an effective polyvalent cytotoxic response.

Simple synthesis and functionalization of iron nanoparticles for magnetic resonance imaging.

Magnetic nanoparticles (NPs) are increasingly important in many biomedical applications, such as drug delivery, hyperthermia, and magnetic resonance imaging (MRI) contrast enhancement. For MRI, iron oxide NPs are the only commercial T2 or negative contrast agents, due to their biocompatibility and ease of synthesis and research in the area is highly active. The efficacy of these contrast agents depends mainly on the surface chemistry and magnetic properties of the NPs. Materials with larger magnetization could induce more efficient transverse (T2) relaxation of protons and result in greater contrast enhancement. As iron has the highest saturation magnetization at room temperature among all elements, and is biocompatible, it is an ideal candidate for MRI contrast enhancement. Nevertheless, the development of using iron NPs for magnetic applications has been challenging and limited compared to those of its oxides, due to the difficulty in preparing stable iron NPs with simple synthesis methods and precursors. 6] Under ambient conditions, iron NPs of 8 nm or smaller oxidize completely upon exposure to air. For larger NPs, an oxide shell of 3–4 nm forms instantly on the surface, forming iron/iron oxide core/shell NPs. Groundbreaking studies for the synthesis of iron NPs of larger than 8 nm has largely been achieved by decomposition of iron pentacarbonyl, [Fe(CO)5]. [6,8] Additional reports include the use of other precursors in forming iron nanocubes. However, all of these processes are limited in terms of ease of synthesis and scalability; [Fe(CO)5] is volatile and highly toxic, [5] and other processes involve precursors that are expensive and airsensitive, or require high decomposition temperatures. Here, we chose an easy to handle iron organometallic sandwich compound as the precursor and prepared singlecrystal iron NPs using a simple, low-temperature synthesis method. The iron nanocrystals oxidized naturally to form highly crystalline iron/iron oxide core/shell NPs. The ease of this synthesis facilitates the larger-scale application of stabilized iron NPs. To enable the use of these NPs in biological applications, the NP surface was modified to make the NPs water soluble. The strongly magnetic core/shell NPs are shown to be more effective T2 contrast agents for in vivo MRI and small tumor detection, compared to pure iron oxides. The successful detection of small tumors in vivo demonstrated here holds a great promise for accurate detection of early metastases in human lymph nodes, which has a large impact on the treatment and prognosis of a range of cancers. The iron/iron oxide core/shell NPs were prepared by first synthesizing iron nanocrystals by decomposition of the iron precursor [Fe(C5H5)(C6H7)], in the presence of oleylamine (OLA) stabilizing molecules. The non-carbonyl, sandwich compound was chosen for its simple preparation and ease of decomposition compared to other more stable sandwich compounds such as ferrocene. The synthesis was carried out in a closed reaction vessel under a mild hydrogen atmosphere, at 130 8C. The temperature required was lower than the usual temperature range (150–300 8C) needed for decomposition of other iron precursors in previous studies. Once [*] Dr. K. W. Feindel, Prof. P. T. Callaghan, Prof. R. D. Tilley School of Chemical and Physical Sciences and The MacDiarmid Institute for Advanced Materials and Nanotechnology, Victoria University of Wellington, Wellington 6012 (New Zealand) Fax: (+ 64)4-463-5237 E-mail: richard.tilley@vuw.ac.nz Dr. S. Cheong, Dr. B. Ingham Industrial Research Limited and The MacDiarmid Institute for Advanced Materials and Nanotechnology P. O. Box 31-310, Lower Hutt 5040 (New Zealand) Dr. P. Ferguson, Dr. I. F. Hermans Malaghan Institute of Medical Research P. O. Box 7060, Wellington 6012 (New Zealand)

Tumor immunotherapy by epicutaneous immunization requires langerhans cells.

A role for Langerhans cells (LC) in the induction of immune responses in the skin has yet to be conclusively demonstrated. We used skin immunization with OVA protein to induce immune responses against OVA-expressing melanoma cells. Mice injected with OVA-specific CD8+ T cells and immunized with OVA onto barrier-disrupted skin had increased numbers of CD8+ T cells in the blood that produced IFN-γ and killed target cells. These mice generated accelerated cytotoxic responses after secondary immunization with OVA. Prophylactic or therapeutic immunization with OVA onto barrier-disrupted skin inhibited the growth of B16.OVA tumors. LC played a critical role in the immunization process because depletion of LC at the time of skin immunization dramatically reduced the tumor-protective effect. The topically applied Ag was presented by skin-derived LC in draining lymph nodes to CD8+ T cells. Thus, targeting of tumor Ags to LC in vivo is an effective strategy for tumor immunotherapy.

Side population is not necessary or sufficient for a cancer stem cell phenotype in glioblastoma multiforme.

There is strong evidence for the existence of cancer stem cells (CSCs) in the aggressive brain tumor glioblastoma multiforme (GBM). These cells have stem‐like self‐renewal activity and increased tumor initiation capacity and are believed to be responsible for recurrence due to their resistance to therapy. Several techniques have been used to enrich for CSC, including growth in serum‐free defined media to induce sphere formation, and isolation of a stem‐like cell using exclusion of the fluorescent dye Hoechst 33342, the side population (SP). We show that sphere formation in GBM cell lines and primary GBM cells enriches for a CSC‐like phenotype of increased self‐renewal gene expression in vitro and increased tumor initiation in vivo. However, the SP was absent from all sphere cultures. Direct isolation of the SP from the GBM lines did not enrich for stem‐like activity in vitro, and tumor‐initiating activity was lower in sorted SP compared with non‐SP and parental cells. Transient exposure to doxorubicin enhanced both CSC and SP frequency. However, doxorubicin treatment altered the cytometric profile and obscured the SP demonstrating the difficulty of identifying SP in cells under stress. Doxorubicin‐exposed cells showed a transient increase in SP, but the doxorubicin‐SP cells were still not enriched for a stem‐like self‐renewal phenotype. These data demonstrate that the GBM SP does not necessarily contribute to self‐renewal or tumor initiation, key properties of a CSC, and we advise against using SP to enumerate or isolate CSC. STEM CELLS 2011;29:452–461

High Avidity Antigen-Specific CTL Identified by CD8-Independent Tetramer Staining

Tetrameric MHC/peptide complexes are important tools for enumerating, phenotyping, and rapidly cloning Ag-specific T cells. It remains however unclear whether they can reliably distinguish between high and low avidity T cell clones. In this report, tetramers with mutated CD8 binding site selectively stain higher avidity human and murine CTL capable of recognizing physiological levels of Ag. Furthermore, we demonstrate that CD8 binding significantly enhances the avidity as well as the stability of interactions between CTL and cognate tetramers. The use of CD8-null tetramers to identify high avidity CTL provides a tool to compare vaccination strategies for their ability to enhance the frequency of high avidity CTL. Using this technique, we show that DNA priming and vaccinia boosting of HHD A2 transgenic mice fail to selectively expand large numbers of high avidity NY-ESO-1157–165-specific CTL, possibly due to the large amounts of antigenic peptide delivered by the vaccinia virus. Furthermore, development of a protocol for rapid identification of high avidity human and murine T cells using tetramers with impaired CD8 binding provides an opportunity not only to monitor expansion of high avidity T cell responses ex vivo, but also to sort high avidity CTL clones for adoptive T cell transfer therapy.

Dendritic Cell Function Can Be Modulated through Cooperative Actions of TLR Ligands and Invariant NKT Cells

The quality of signals received by dendritic cells (DC) in response to pathogens influences the nature of the adaptive response. We show that pathogen-derived signals to DC mediated via TLRs can be modulated by activated invariant NKT (iNKT) cells. DC maturation induced in vivo with any one of a variety of TLR ligands was greatly improved through simultaneous administration of the iNKT cell ligand α-galactosylceramide. DC isolated from animals treated simultaneously with TLR and iNKT cell ligands were potent stimulators of naive T cells in vitro compared with DC from animals treated with the ligands individually. Injection of protein Ags with both stimuli resulted in significantly improved T cell and Ab responses to coadministered protein Ags over TLR stimulation alone. Ag-specific CD8+ T cell responses induced in the presence of the TLR4 ligand monophosphoryl lipid A and α-galactosylceramide showed faster proliferation kinetics, and increased effector function, than those induced with either ligand alone. Human DC exposed to TLR ligands and activated iNKT cells in vitro had enhanced expression of maturation markers, suggesting that a cooperative action of TLR ligands and iNKT cells on DC function is a generalizable phenomenon across species. These studies highlight the potential for manipulating the interactions between TLR ligands and iNKT cell activation in the design of effective vaccine adjuvants.